Strides Pharma Science · NSE: STAR · BSE: 532531

Q3 FY23 results · Oct–Dec 2022

Strides Pharma Science reported revenue from operations of ₹864.85 crore (up 8.9% from Q3 FY22) and net loss of ₹82.11 crore for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY23	Q3 FY22	YoY	Q2 FY23	QoQ
Revenue from operations	864.85	794.39	+8.9%	897.10	−3.6%
Other income	26.20	10.19	+157.1%	23.46	+11.7%
Total income	891.05	804.58	+10.7%	920.56	−3.2%
Profit before share of associates & JVs and tax	65.44	(106.86)	Turned profit	6.77	+867.1%
Share of profit/(loss) of associates & JVs	(143.45)	(24.27)		(44.84)
Net profit for the period	(82.11)	(126.66)	Loss narrowed	18.90	Turned loss
Attributable to shareholders of the company	(80.03)	(121.67)	Loss narrowed	22.82	Turned loss
EPS, basic (₹)	(8.86)	(13.55)	Loss narrowed	2.54	Turned loss
Net margin (%)	-9.5	-15.9		2.1

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY23	Q3 FY22	YoY	Q2 FY23	QoQ
Revenue from operations	386.51	439.56	−12.1%	481.24	−19.7%
Other income	29.75	7.50	+296.8%	20.47	+45.3%
Total income	416.27	447.06	−6.9%	501.71	−17.0%
Profit before tax	17.99	(31.69)	Turned profit	(44.07)	Turned profit
Net profit for the period	12.54	(17.60)	Turned profit	(4.00)	Turned profit
EPS, basic (₹)	1.39	(1.96)	Turned profit	(0.44)	Turned profit
Net margin (%)	3.2	-4.0		-0.8

Consolidated

Filed with BSE: 25 Jan 2023, 11:08 IST
Board meeting: 24 Jan 2023
Period: 01 Oct 2022 to 31 Dec 2022
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 25 Jan 2023, 11:08 IST
Board meeting: 24 Jan 2023
Period: 01 Oct 2022 to 31 Dec 2022
Review status: Unaudited
Source: XBRL filing on BSE